Phase 2 Study Presented at Late-breaking Session during the 25th European Academy of Dermatology and Venereology Congress October 03, 2016 07:00 AM Eastern Daylight Time VIENNA, Austria–(BUSINESS WIRE)–Positive Phase 2 study results with THVD-102, a combination drug product for the treatment of primary focal hyperhidrosis, or excessive sweating, were presented on October 1, 2016 at […]
BASEL, Switzerland, April 3, 2018 /PRNewswire/ — Dermavant Sciences, a biopharmaceutical company focused on developing innovative therapies for dermatologic conditions, today announced that it has expanded its pipeline by inlicensing an investigational drug for the treatment of multi-focal hyperhidrosis. It has also strengthened its management team through the appointment of David Rubenstein, M.D., Ph.D., as […]
TheraVida is dedicated to the development of new therapies to improve the lives of patients with hyperhidrosis